Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

Main Article Content

Mark Lebwohl
Leon Kircik
Angela Moore
Linda Stein Gold
James Del Rosso
Zoe Draelos
Melinda Gooderham
Lawrence Green
Adelaide Herbert
Kim Papp
Jerry Bagel
Neal Bhatia
Laura Ferris
Terry Jones
Steve Kempers
David Pariser
Paul Yamauchi
Matthew Zirwas
Amy Feng
Patrick Burnett
Robert Higham
David Berk

Keywords

rofumilast, psoriasis, DERMIS phase 3 trials

Abstract

N/A

References

1. Elmets CA, et al. J Am Acad Dermatol 2021;84:432-470.

2. Lebwohl MG, et al. N Engl J Med 2020;383:229-239.

Most read articles by the same author(s)

<< < 12 13 14 15 16 17 18 19 > >>